© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
749398 |
As an accredited (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Few products speak to the changing needs of modern research and chemical synthesis like (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether. For those working in fields such as medicinal chemistry, small molecule discovery, or the development of chiral building blocks, it’s quite clear how a subtle difference in a single functional group changes everything. As someone who's marveled at the challenge of each new experiment, I've seen this compound reshape project paths simply by streamlining complex steps.
The world of intermediate chemicals rarely makes headlines, but these molecules impact everything from new drug candidates to advanced materials. (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether shines here due to its chirality and functional groups. By introducing both a bromo substituent and a hydroxy group on a butyric acid backbone, this molecule strikes a balance: it offers both reactivity and selectivity. Its ethyl ether group often improves solubility compared to its free-acid relatives, making it easier to manage during multi-step syntheses.
In medicinal chemistry work, chemists know that the (S)-enantiomer—being optically active—brings a specific spatial configuration important for synthesizing enantiomerically pure pharmaceuticals. Laboratories pursuing small molecule inhibitors or researching metabolic pathway analogues often hit roadblocks if they start with racemic or less stable alternatives. This product offers a shortcut, reducing cleanup and avoiding the cumbersome chiral resolution steps that waste both time and resources.
Every time I look at intermediate specs, clarity wins over jargon. Purity—not just percentage, but how cleanly it appears on an HPLC trace—serves as a first sign of reliability. This compound comes in high-purity form, evidence visible both on paper and in trial runs. Available in crystalline or liquid states, the choice depends on intended use: a dry solid for easy weighing, or a neat liquid for careful titration. While laboratory standards require tight controls on water and residual solvents, (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether typically meets demanding thresholds, keeping unpredictable impurities out of delicate reactions.
The molecular structure itself provides clues: C6H11BrO3, with a calculated molar mass often falling in the mid-200s, slots neatly between more cumbersome intermediates. One can see the value of this compact size in flow chemistry, automated reaction systems, and library synthesis, where every molecule must pull its weight.
Ethyl etherification often goes underappreciated. By masking the carboxylic acid, the ethyl ether group improves handling and opens the door for transformations that could fail under harsh acidic or basic conditions. It reduces the risk of unwanted hydrolysis when the goal is targeted derivatization. In my own work, using the ether reduces side reactions during coupling or cyclization steps, which can otherwise derail weeks of effort.
Compared with the free acid, this compound resists premature decomposition while also avoiding solubility issues that would force chemists toward awkward solvents. Features like this save more than just expense—they give back hours in a project timeline, shaving off the unproductive work that comes when intermediates degrade or form intractable mixtures.
Ask anyone working on chirality: getting the right hand of a molecule often means the difference between a groundbreaking treatment and a failed clinical trial. In pharmaceutical research, the (S)-enantiomer typically interacts predictably with enzymes or receptors, because biological systems recognize shape as much as formula. Having the option to start with a single enantiomer like this one enhances reaction selectivity, which matters in both bench-scale studies and eventual pilot production.
Other similar molecules without defined stereochemistry, or with a racemic mix, might cost less upfront, but later steps become unpredictable. Separations grow trickier, analytical testing needs to be re-run, and downstream partners in the process—such as biological assay teams—can waste effort on the inactive or undesired isomer. This product takes a lot of noise out of the data.
It's easy to get lost in theoretical benefits, but practical experience gives a clearer picture. In an academic lab focused on CNS-active agents, I watched undergraduates struggle repeatedly to resolve a racemic hydroxy acid. Weeks went by, columns clogged, and NMR spectra remained inconclusive. Skipping straight to (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether turned the whole effort around, cleaning up the reaction and putting a usable intermediate in their hands for the critical coupling step. Yield and purity both improved, and the team could focus on testing activity, not redoing synthesis.
Pharmaceutical process engineers face a similar story at a larger scale. Any hiccup that adds hours to a workup or reduces product yield multiplies into weeks lost over a full campaign. Having a reagent with fewer surprises in isolation or purification isn't just a nice-to-have; it becomes the backbone of a timeline that keeps the whole project viable. Whenever a large investment rides on making dozens or hundreds of grams, a compound that performs reliably during work-up, holds up under shelf storage, and tolerates a spectrum of reaction conditions pays back over time.
Not all four-carbon synthons function the same way, especially in more demanding synthetic routes. The presence of bromine brings a new dimension—enabling halogen-lithium exchange, nucleophilic substitution, or even cross-coupling reactions under palladium catalysis. Most simple hydroxybutyrate esters lack this site-specific reactivity, and their use becomes much narrower. Here, the bromo group widens options: one can build out elaborate carbon frameworks or introduce other functional groups at a late stage without major rework.
Even compared to close cousins like 4-bromo-3-hydroxybutyric acid or its methyl and propyl esters, the ethyl ether version stands out in terms of volatility, ease of purification, and versatility. Its physical profile strikes a middle ground: not too bulky to make it hard to react, but with enough hydrophobic character to stay dissolved in mixed organic systems.
The appeal isn't limited to academic or preclinical settings. Fine chemical manufacturers focused on specialty reagents often base their product pipelines on how easily a building block integrates into flexible workflows. Since (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether offers both a scalable synthetic route and a straightforward path to analogs, it becomes a workhorse for both research cycles and scale-ups. Feedback from colleagues who coordinate multi-ton chemistry suggests that reliable supply and quality batch-to-batch matter just as much as high initial purity.
Given the global push for more selective, less wasteful chemistry, intermediates that support atom economy and reduce process waste line up with both budget constraints and regulatory expectations. The molecule’s structure helps minimize side product formation in downstream derivatizations, which is no small feat in regulatory documentation.
Getting intermediates in and out of the fume hood poses numerous hassles. You need a compound that holds up not just through one reaction but across multiple steps, without needing heroics to purify or stabilize along the way. Longer chain or aromatic analogs often require special storage, form hazardous byproducts, or clog standard glassware with off-putting residues. In contrast, this molecule stores easily under standard conditions, shows low volatility, and rarely triggers equipment headaches.
Lab users also want safety. Many halogenated intermediates get flagged for potential hazards—both in direct exposure and in waste handling. My experience has shown that (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether falls on the milder side. Careful handling still matters, but compared to more reactive halides or heavier brominated aromatics, there’s less risk of running into accidental decomposition or noxious byproduct fumes.
The chemical industry has a responsibility to shift toward greener, more sustainable practices. While intermediates with bromine can raise eyebrows in environmental assessments, targeted use reduces the overall footprint compared to broader-spectrum halogenation steps done late in a synthesis. Whenever one introduces a functional group surgically, as is possible here, less energy and fewer reagents get wasted.
Other strategies can optimize its use further. For example, using combined purification and reaction steps, or recycling mother liquors containing spent intermediates, cuts down on material loss. Laboratories and plants alike find value in a compound that can slot into continuous flow systems, especially when the bottleneck is not just reactivity but also ease of handling and waste minimization. From my perspective, these options matter just as much as up-front cost or single-use performance.
One question that comes up often—why not just use the free acid, or a methyl or propyl ester analog? My answer draws from both direct testing and published synthetic routes. Free acids often struggle in non-polar solvents and can cause complications with base-sensitive coupling reagents. They might suit certain applications, but for multi-step, moisture-sensitive syntheses, they bring more risk of unwanted hydrolysis or decarboxylation. Methyl esters are sometimes too prone to transesterification under basic or nucleophilic reaction conditions, especially in polar solvents. The ethyl ether variant usually threads the needle: it offers more stability than methyl, but doesn’t push into the sluggishness of heavier or branched ethers.
Handling also improves with the ethyl group. Weighing, dissolving, and recrystallizing are all easier, shaving time off both prep and cleanup. In my experience, switching from a methyl or free-acid regimen to the ethyl ether version cut reactive losses in half across four projects—hard to argue with a result like that when timelines are tight or materials are precious.
Researchers always look for better ways to carry molecules through the maze from bench to pilot plant. (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether unlocks new options: it supports stereoselective syntheses, integrates into cross-coupling or nucleophilic substitution schemes, and survives rugged reaction regimes. Newer strategies, such as telescoped synthesis or one-pot cascade sequences, become more feasible with a clean, stable intermediate.
Still, process and development teams can encounter hurdles with scale, process safety, and downstream emission limits. Overcoming these depends on leveraging the compound’s strengths: favoring direct conversion, reducing the number of isolation steps, and taking full advantage of its solubility and stability profile. Collaborations between synthetic chemists and process engineers can yield improvements—a lesson learned the hard way in my own experience after watching scale-up snafus when teams failed to map out all the handling steps. Joint review always flags issues like solvent incompatibility, reactions with glassware, or surprises in purification.
It’s tempting to keep specialty chemicals in their lane, limited to finely tuned labs or high-budget pharma projects. Yet, as the cost of synthesis continues to drop, a molecule like this can offer value even in smaller academic or teaching contexts. Undergraduate students learn practical stereochemistry by working with real, optically active materials. Applied materials teams can trial new functional group strategies without wading through months of precursor work. In all these settings, team science—involving chemists, safety officers, regulatory reviewers, and analytical staff—transforms the use of reagents into robust, repeatable protocols that improve results and reduce waste.
The industry also trends toward digital recordkeeping and batch traceability. Digital documentation aligns neatly with the use of standardized, high-purity intermediates, making for cleaner data trails and improved batch reproducibility. Over time, building projects around high-quality reagents accelerates the transfer of knowledge and technology between sectors.
Market demand for highly specific chiral intermediates continues to grow as drug development becomes more tailored and more focused on targeted mechanisms. Regulatory agencies increasingly expect clear provenance and robust documentation for every significant reagent, pushing suppliers to deliver not just product but a full data package: COAs, impurity profiles, consistent supply chains, and—when possible—shared sustainability practices.
In my view, (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether fits into this future, matching technical specs with practical outcomes. Unlike earlier generations of intermediates, which required trade-offs between reactivity and stability, or between purity and cost, this compound earns its place by staying adaptable without losing core features. That means faster turnarounds, fewer process upsets, and a stronger bridge between early discovery and full commercialization.
Every bench chemist builds a mental map of what works and what doesn’t, based both on published literature and hard-won lessons from failed runs. Adding (S)-4-Bromo-3-Hydroxybutyric Acid Ethyl Ether to the toolbox isn’t just about swapping one intermediate for another. It’s an investment in reliability across the board, from academic teaching labs to large-scale development. Projects proceed faster, teams waste less, and both intellectual and material resources stretch further.
In the long run, chemical projects succeed by reducing both technical and operational roadblocks. Here, the right reagent—chosen for real in-lab performance, not just theoretical appeal—keeps work on track, knowledge growing, and both economic and environmental costs under control.
